Home > Publications database > Prostate Cancer Screening in Young Men. > print

001     292542
005     20260220120930.0
024 7 _ |a 10.3390/jpm14080818
|2 doi
024 7 _ |a pmid:39202010
|2 pmid
024 7 _ |a pmc:PMC11355119
|2 pmc
037 _ _ |a DKFZ-2024-01785
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a de Vrieze, Maxime
|0 P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4
|b 0
|e First author
|u dkfz
245 _ _ |a Prostate Cancer Screening in Young Men.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1725629000_31211
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C130#LA:C130#
520 _ _ |a Background: Prostate cancer (PCa) screening strategies are being developed and evaluated in several countries. However, most of the evidence regarding PCa screening has been generated in study populations aged 50 and older. Aims: This study summarizes findings of a screening trial in younger men and discuss those findings in the context of other screening trials. Methods: Non-systematic review. Results: Screening of 45-year-old men resulted in a low PCa detection rate. Nonetheless, almost 70% of screen-detected PCa at this age was clinically significant. In young men ISUP GG 1 screen-detected cancers warrant rigorous follow-up. A baseline, midlife prostate-specific antigen (PSA) value at age 45 may safely exclude the vast majority of men from further screening investigations for at least 5 years. At age 45, a confirmatory PSA value reduces the number of subsequent tests almost by half. Sequential magnetic resonance imaging (MRI) as a reflex test subsequent to an elevated PSA ≥ 3 ng/mL needs further investigation in young men. Conclusions: Screening in young men needs to be carefully investigated in order to avoid overscreening and overdiagnosis.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PSA
|2 Other
650 _ 7 |a baseline PSA
|2 Other
650 _ 7 |a multiparametric MRI
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a prostate cancer screening
|2 Other
650 _ 7 |a risk-adapted screening
|2 Other
700 1 _ |a Al-Monajjed, Rouvier
|0 P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811
|b 1
|u dkfz
700 1 _ |a Boschheidgen, Matthias
|0 0000-0002-1522-6374
|b 2
700 1 _ |a Albers, Peter
|0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.3390/jpm14080818
|g Vol. 14, no. 8, p. 818 -
|0 PERI:(DE-600)2662248-8
|n 8
|p 818
|t Journal of Personalized Medicine
|v 14
|y 2024
|x 2075-4426
856 4 _ |y OpenAccess
|u https://inrepo02.dkfz.de/record/292542/files/jpm-14-00818.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://inrepo02.dkfz.de/record/292542/files/jpm-14-00818.pdf?subformat=pdfa
909 C O |o oai:inrepo02.dkfz.de:292542
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)3cb0e3df380b462dd19c8f931cd090d4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)555d0aa06e51f29f46d788ff54fc6811
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-29
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:01:05Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:05Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:05Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-29
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-29
920 2 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 0 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-He78)C130-20160331
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21